share_log

University Of Minnesota Masonic Cancer Center Intends To Expand Cirtrus Pharmaceuticals' Ongoing Investigator-Initiated Phase 1 Trial Of LYMPHIR In Combination With FDA-Approved CAR-T Products For B-cell Lymphomas

Moomoo 24/7 ·  Apr 11 08:40

National Cancer Institute (NCI)-designated research and treatment center City of Hope, in Duarte, CA, to participate in the University of Minnesota (UMN) Masonic Cancer Center's ongoing Phase 1 trial to determine the maximum tolerated dose of LYMPHIR plus CAR-T therapy

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment